Treatment of chronic hepatitis C—how much interferon is enough?
Author:
- 1 April 2010
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 7 (4) , 191-193
Abstract
A multicenter, randomized, controlled trial of 610 patients with chronic hepatitis C infected with HCV genotype 1 or 4 compared 48 weeks of standard of care therapy (PEG-IFN and ribavirin) with 12 weeks of induction therapy with high-dose PEG-IFN followed by 36 weeks of standard of care treatment. High-dose PEG-IFN induction therapy did not enhance early or sustained virologic response rates compared with standard of care therapy.Keywords
This publication has 10 references indexed in Scilit:
- Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open-Label StudyClinical Gastroenterology and Hepatology, 2010
- Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial† ‡Hepatology, 2009
- Intracellular Innate Immune Cascades and Interferon Defenses That Control Hepatitis C VirusJournal of Interferon & Cytokine Research, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2bAnnals of Internal Medicine, 2009
- Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4Antiviral Therapy, 2008
- Hepatitis C virus infection and apoptosisWorld Journal of Gastroenterology, 2007
- Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons?Journal of Hepatology, 2004
- Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirinHepatology, 2002
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998